| Date Filed | Type | Description |
| 08/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob... |
| 08/14/2023 |
4
| Kim Hyung Heon (CEO & President) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 625,064 shares
@ $0 |
|
| 08/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 08/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 07/28/2023 |
4
| KOVEN ANDREW I (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 87,500 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4
| Salsbury Michael (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 87,500 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4
| STRICKLAND D GORDON (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 87,500 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4
| GROVES JASON L (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 87,500 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4
| Glickman Mark A (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4
| Kim Na Yeon (10% Owner) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 87,500 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 07/28/2023 |
4/A
| Kim Na Yeon (10% Owner) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Acquired 4,671 shares
@ $0 |
|
| 06/29/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 06/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/16/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
3
| Glickman Mark A (Director) has filed a Form 3 on NeuroBo Pharmaceuticals, Inc. |
| 05/12/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/02/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 04/17/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/28/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/27/2023 |
8-K/A
| Quarterly results |
| 03/13/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Altium Capital Management LP reports a 0% stake in NeuroBo Pharmaceuticals, Inc. |
| 02/09/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 02/01/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 02/01/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/23/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|